BRPI0410562A - molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo - Google Patents

molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo

Info

Publication number
BRPI0410562A
BRPI0410562A BRPI0410562A BRPI0410562A BR PI0410562 A BRPI0410562 A BR PI0410562A BR PI0410562 A BRPI0410562 A BR PI0410562A BR PI0410562 A BRPI0410562 A BR PI0410562A
Authority
BR
Brazil
Prior art keywords
release
expression
vehicle
target polypeptides
purification
Prior art date
Application number
Other languages
English (en)
Inventor
Vidadi Yusibov
Vadim Mett
Konstantin Musiychuk
Original Assignee
Fralunhofer Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fralunhofer Usa Inc filed Critical Fralunhofer Usa Inc
Publication of BRPI0410562A publication Critical patent/BRPI0410562A/pt
Publication of BRPI0410562B1 publication Critical patent/BRPI0410562B1/pt
Publication of BRPI0410562B8 publication Critical patent/BRPI0410562B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2448—Licheninase (3.2.1.73)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01073—Licheninase (3.2.1.73)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

"MOLéCULA RECOMBINANTE DE VEìCULO PARA EXPRESSãO, LIBERAçãO E PURIFICAçãO DE POLIPEPTìDEOS ALVO". Molécula recombinante de veículos que têm seqüências de aminoácidos de enzimas termo-estáveis e métodos de uso para expressão, recuperação e liberação de seqüências estranhas (de peptídeos e polipeptídeos) produzidas em diferentes sistemas (bactérias, levedura, DNA, culturas de células como culturas de células de mamífero, de planta, de inseto, protoplasto e plantas inteiras ín vitro ou in vivo) são fornecidos. A molécula recombinante de veículo que usa seqüências de liquenase B (Lic B) também foi feita e usada como parte da proteína de veículo para expressar, recuperar e liberar uma variedade de polipeptídeos alvo de interesse.
BRPI0410562A 2003-05-22 2004-05-24 proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira BRPI0410562B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47249503P 2003-05-22 2003-05-22
US60/472,495 2003-05-22
PCT/US2004/016452 WO2005026375A2 (en) 2003-05-22 2004-05-24 Recombinant carrier molecule for expression, delivery and purification of target polypeptides

Publications (3)

Publication Number Publication Date
BRPI0410562A true BRPI0410562A (pt) 2006-06-20
BRPI0410562B1 BRPI0410562B1 (pt) 2019-09-03
BRPI0410562B8 BRPI0410562B8 (pt) 2021-05-25

Family

ID=34312145

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410562A BRPI0410562B8 (pt) 2003-05-22 2004-05-24 proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira

Country Status (8)

Country Link
US (4) US20060265787A1 (pt)
EP (1) EP1664322B1 (pt)
CN (2) CN1833030B (pt)
AU (2) AU2004272972A1 (pt)
BR (1) BRPI0410562B8 (pt)
CA (1) CA2526720C (pt)
ES (1) ES2427641T3 (pt)
WO (1) WO2005026375A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
ES2531125T3 (es) 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
EP1769068B1 (en) * 2004-02-20 2014-12-31 iBio, Inc. Systems and methods for clonal expression in plants
JP2009502207A (ja) 2005-08-03 2009-01-29 フラウンホーファー ユーエスエー， インコーポレイテッド イムノグロブリンの産生のための組成物および方法
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
BRPI0707733B1 (pt) * 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
KR20080106434A (ko) * 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 Ｈｐｖ 항원, 백신 조성물 및 관련된 방법
CA2642138A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Production of foreign nucleic acids and polypeptides in plant systems
EP2152301A4 (en) * 2007-04-28 2010-07-28 Fraunhofer Usa Inc TRYPANOSOMAANTIGEN, VACCINE COMPOSITIONS AND RELATED METHODS
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009026397A2 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
EP2352751A2 (en) * 2008-09-28 2011-08-10 Fraunhofer USA, Inc. Plasmodium vaccines, antigens, compositions and methods
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US9913890B2 (en) 2012-06-22 2018-03-13 Pharma Green Llc Methods and compositions for emergency post-infection treatment of anthrax
CN112955218A (zh) 2018-06-29 2021-06-11 Ge营养有限公司 用于使用来自藿香蓟属物种的提取物来改善和管理良性前列腺肥大(bph)和相关衰老症状的草药提取物组合物和方法
WO2021183780A1 (en) * 2020-03-11 2021-09-16 Ibio, Inc. Lichenase-covid-19 based vaccine

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS61176721A (ja) 1985-01-31 1986-08-08 Mochizuki Motor Kk マンホ−ル蓋の開閉運搬装置
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2130436C (en) 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US6103511A (en) * 1996-10-04 2000-08-15 University Of Georgia Research Foundation, Inc. Lichenase and coding sequences
WO1998014595A1 (en) * 1996-10-04 1998-04-09 University Of Georgia Research Foundation Inc. Fungal lichenase and coding sequences
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
NZ538399A (en) 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
IL141312A0 (en) 1998-08-11 2002-03-10 Biosource Tech Inc Method for recovering proteins from the interstitial fluid of plant tissues
BR9915919A (pt) 1998-10-07 2001-08-21 Syngenta Participations Ag Proteìnas terapeuticamente ativas em plantas
WO2000025574A1 (en) 1998-10-30 2000-05-11 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
EP1147178A1 (en) 1999-02-05 2001-10-24 Thomas Jefferson University Production of biomedical peptides and proteins in plants using transcomplementation systems
US6734173B1 (en) 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
WO2001070663A2 (en) 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
MXPA02012254A (es) 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
EP1294905A1 (en) 2000-06-26 2003-03-26 SmithKline Beecham Biologics SA Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
ATE500336T1 (de) 2001-12-26 2011-03-15 Univ Central Florida Expression von schutzantigenen in transgenen chloroplasten und herstellung verbesserter impfstoffe
US20040170606A1 (en) 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
US7683238B2 (en) 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
ES2531125T3 (es) 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
BRPI0410342A (pt) 2003-05-05 2006-06-20 Dow Agrosciences Llc composições imunoprofiláticas e terapêuticas estáveis derivadas de células vegetais transgênicas e processos para produção
KR20060035596A (ko) 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CZ297389B6 (cs) 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
EP1682667B1 (en) 2003-11-10 2010-05-26 Icon Genetics GmbH Rna virus-derived plant expression system
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
EP1769068B1 (en) 2004-02-20 2014-12-31 iBio, Inc. Systems and methods for clonal expression in plants
ES2376337T3 (es) 2004-03-03 2012-03-13 Iq Therapeutics Bv Anticuerpos monoclonales neutralizantes de la toxina del �?ntrax humanos y métodos para su uso.
US7888135B2 (en) 2004-04-23 2011-02-15 University Of Georgia Research Foundation, Inc. Diagnostic assay for Trypanosoma cruzi infection
JP4980895B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
EP1616959A1 (en) 2004-07-07 2006-01-18 Icon Genetics AG Biological safe transient protein expression in plants
EP1827489B1 (en) 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP1885395A4 (en) 2005-05-16 2009-12-02 Merck & Co Inc METHOD FOR IMPROVING THE IMMUNOGENICITY OF PLASMODIUM ANTIGENES
WO2007089753A2 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US8277816B2 (en) 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
CA2642138A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Production of foreign nucleic acids and polypeptides in plant systems
BRPI0707733B1 (pt) 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
KR20080106434A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 Ｈｐｖ 항원, 백신 조성물 및 관련된 방법
AU2007261196A1 (en) 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
CN104140958A (zh) 2006-08-09 2014-11-12 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
AU2007295073A1 (en) 2006-09-15 2008-03-20 Fraunhofer Usa, Inc. Influenza antibodies, compositions, and related methods
EP2086577B1 (en) 2006-10-16 2013-03-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Conjugates of the plasmodium falciparum surface protein pfs25 as malaria vaccine
FR2911608B1 (fr) 2007-01-23 2009-04-03 Centre Nat Rech Scient Nouvelles compositions vaccinales anti paludique et ses utilisations.
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
EP2152301A4 (en) 2007-04-28 2010-07-28 Fraunhofer Usa Inc TRYPANOSOMAANTIGEN, VACCINE COMPOSITIONS AND RELATED METHODS
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009026397A2 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
KR20090042652A (ko) 2007-10-26 2009-04-30 주식회사 바이오노트 고병원성 조류 인플루엔자 바이러스 감염증을 위한 항체치료방법
US20090297550A1 (en) 2007-10-31 2009-12-03 Henry Daniell Chloroplast-derived human vaccine antigens against malaria
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof

Also Published As

Publication number Publication date
US8591909B2 (en) 2013-11-26
US8173408B2 (en) 2012-05-08
CN1833030A (zh) 2006-09-13
US20120282288A1 (en) 2012-11-08
ES2427641T3 (es) 2013-10-31
WO2005026375A2 (en) 2005-03-24
US9012199B2 (en) 2015-04-21
CN1833030B (zh) 2014-07-23
US20100227373A1 (en) 2010-09-09
AU2010200667A1 (en) 2010-03-18
CA2526720A1 (en) 2005-03-24
EP1664322B1 (en) 2013-07-10
US20060265787A1 (en) 2006-11-23
BRPI0410562B8 (pt) 2021-05-25
AU2004272972A1 (en) 2005-03-24
AU2010200667B2 (en) 2013-03-14
CN103074316B (zh) 2015-10-21
EP1664322A4 (en) 2007-01-10
US20140141508A1 (en) 2014-05-22
CN103074316A (zh) 2013-05-01
EP1664322A2 (en) 2006-06-07
WO2005026375A3 (en) 2006-03-02
CA2526720C (en) 2013-10-22
BRPI0410562B1 (pt) 2019-09-03

Similar Documents

Publication Publication Date Title
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
DE602006020617D1 (de) Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
DE60336228D1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
CY1112110T1 (el) Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
ATE500323T1 (de) Subtilisin-variante
EP3756690A3 (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR0008772B1 (pt) vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
WO2007147014A3 (en) Method and systems for using biopolymer-based beads and hydrogels
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
UY24367A1 (es) Vacunas contra tumores y procedimiento para su produccion
CN116528889A8 (zh) 用于治疗胶质母细胞瘤的方法和组合物
BR112023025331A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
MXPA03006984A (es) Secuencia de nucleotidos que median la fertilidad masculina y metodo de uso de la misma.
AR051837A1 (es) Produccion de proteinas de fusion recombinante dentro de ensamblajes similares a cuerpos proteicos recombinantes (escpr)
AR043862A1 (es) Procedimiento para la obtencion de estirpes celulares de mastocitos a partir de tejidos de cerdo y procedimiento para la produccion de moleculas de tipo de la heparina
BR0313083A (pt) moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
DE60219361D1 (de) Verfahren zur rekombinanten herstellung von plazenta wachstumsfaktor
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12P 21/06 , C12N 9/00 , C12N 9/24 , C12N 1/20 , C12N 15/00 , C07H 21/04

Ipc: C07K 19/00 (2006.01), C12P 21/06 (2006.01), C12N 9

B25A Requested transfer of rights approved

Owner name: IBIO, INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2828 DE 18/03/2025 POR TER SIDO INDEVIDA.